BeyondSpring
Pharmaceutical ManufacturingNew York, United States51-200 Employees
BeyondSpring is a global biopharmaceutical company based in New York, focused on developing cancer therapies to improve clinical outcomes. It pursues development in major markets including China and the United States, led by its lead asset plinabulin, which aims to address both cancer progression and chemotherapy-induced neutropenia. The company also maintains three preclinical immuno-oncology assets and majority ownership of SEED Therapeutics, a subsidiary advancing a targeted protein degradation platform. In a Phase 3 trial in non-squamous EGFR wild-type NSCLC, the combination of plinabulin with docetaxel extended overall survival versus docetaxel alone in second- to third-line settings. A separate Phase 3 program for CIN prevention with plinabulin plus G-CSF has demonstrated positive data and earned Breakthrough status in the U.S. and China, and the company announced a leadership transition to focus on completing the DUBLIN-4 confirmatory study, effective July 1, 2026.
1-888-653-2347 
support@leadiq.com 
